Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Renewable energy

- PMLiVE

Novo Nordisk completes acquisition of Forma Therapeutics in deal worth $1.1bn

The acquisition includes a pipeline of haemoglobinopathies including etavopivat

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

- PMLiVE

Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn

The acquisition will focus on expanding the company’s blood disorders portfolio

- PMLiVE

Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment

More than 4.9 million people in the UK have diabetes, around 90% of which have type 2 diabetes

- PMLiVE

Novo Nordisk announces positive phase 3 results for haemophilia treatment

Haemophilia affects around 1,125,000 people globally

- PMLiVE

Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis

The companies aim to double diagnostic rates for those with advanced to severe forms of the disease by 2025

- PMLiVE

Novo Nordisk and Flagship Pioneering to collaborate on new research programmes

The companies will focus on rare and cardio-metabolic disease areas

- PMLiVE

Novo Nordisk’s collaboration with MIT and BWH expanded

The new agreement means that the collaboration has been extended until 2026

- PMLiVE

Novo Nordisk growth takes a hit with China deal

Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products

- PMLiVE

Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn

The pharma company has been collaborating with Dicerna on its RNAi gene silencing platform since 2019

- PMLiVE

Novo Nordisk settles US insulin pricing dispute for $100m

Novo Nordisk admits no liability or wrongdoing but will pay investors $100m to “avoid the burden, inherent risk and expense of further litigation”

Top-10 ways that Pharma teams can fight the climate crisis

Ten easy steps that individual medical, marketing, clinical, regulatory, and market access teams can take to reduce their own footprints.

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links